LRRC3C inhibitors as a chemical class comprise a range of compounds that indirectly modulate the activity of the LRRC3C protein by targeting various signaling pathways and cellular processes. These inhibitors impact the protein's function by altering the cellular context in which LRRC3C operates, rather than by direct interaction with the protein itself. This approach to inhibition is particularly relevant when direct inhibitors are unavailable or the complete function of the target protein is not well understood. For example, MEK inhibitors such as PD98059 and U0126 can disrupt the MAPK/ERK pathway, a signaling cascade that regulates numerous cellular activities, including those associated with LRRC3C. By impeding this pathway, these inhibitors can indirectly influence LRRC3C's role within the cell.
Similarly, PI3K/Akt signaling is another pathway that can be modulated by chemicals like LY294002 and Wortmannin. This pathway is involved in cell survival, growth, and metabolism, and its modulation can have a downstream effect on LRRC3C's function. Inhibitors targeting the mTOR pathway, such as Rapamycin, can also play a role in regulating protein synthesis and cell growth, indirectly influencing LRRC3C. Src family kinases, which are targeted by inhibitors like PP2, are involved in various signaling pathways that regulate cell proliferation and differentiation, which could be connected to LRRC3C's regulatory mechanisms. ROCK inhibitor Y-27632 affects the cytoskeleton organization, while NF-κB inhibitor BAY 11-7082 impacts inflammatory responses, both potentially altering the cellular environment in which LRRC3C functions. AMPK inhibitor Dorsomorphin and EGFR inhibitor Gefitinib target metabolic and growth factor signaling, respectively, providing additional avenues through which LRRC3C activity can be modulated. Each of these compounds does not engage directly with LRRC3C but can have a profound impact on the protein's activity by shifting the balance of cellular signaling pathways and processes that govern its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor, can inhibit the MAPK/ERK pathway, potentially altering LRRC3C-involved signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, can affect the PI3K/Akt pathway, which may modulate LRRC3C-related processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, can disrupt the JNK signaling pathway, potentially influencing LRRC3C functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, can affect the p38 MAPK pathway, thereby potentially modulating LRRC3C activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, similar to LY294002, can affect PI3K/Akt signaling involved in LRRC3C-related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor, can inhibit the mTOR pathway, which could interact with signaling involving LRRC3C. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor, can disrupt Src kinase signaling, which may influence LRRC3C-associated pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor, can inhibit Rho-associated protein kinase, which might modulate LRRC3C activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor, can inhibit NF-κB signaling, potentially affecting LRRC3C-related cellular responses. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
AMPK inhibitor, can inhibit the AMPK pathway, potentially altering LRRC3C activity. | ||||||